Table 3 Dosimetric endpoint comparison between Cyberknife and VMAT plans
Average (S.D.) | PTV Dmax (Gy) | Left/Right Carotid Artery Dmax (Gy) | Left/Right Carotid Artery Dmean (Gy) | Thyroid Gland Dmean (Gy) | Spinal Cord Dmax (Gy) | Skin Dmax (Gy) |
Cyberknife | 48.3 (1.2) | 13.9 (4.4) | 6.6 (2.4) | 4.3 (2.2) | 5.8 (2.2) | 41.4 (2.9) |
VMAT-AXB | 46.5* (0.8) | 12.7 (3.1) | 7.1 (2.4) | 2.4* (2.1) | 8.2 (2.2) | 41.3 (3.5) |
VMAT-AAA | 46.6* (0.9) | 12.9 (3.1) | 7.1 (2.4) | 2.7* (2.5) | 7.9 (2.2) | 40.1 (5.0) |
Average (S.D.) | Contralateral Arytenoid Dmax (Gy) | R50 | R20 | Conformity index | MU | |
Cyberknife | 17.9 (4.8) | 5.0 (0.6) | 17.4 (3.0) | 1.13 (0.07) | 7333 (1934) | |
VMAT-AXB | 17.2 (2.9) | 5.9* (0.8) | 20.2 (3.2) | 1.20 (0.10) | 2095* (259) | |
VMAT-AAA | 15.2* (4.0) | 5.7* (0.7) | 19.2 (3.1) | 1.19 (0.05) | 2311* (343) |